Denis Chem Lab

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE051G01012
  • NSEID:
  • BSEID: 537536
INR
86.50
1.57 (1.85%)
BSENSE

Dec 05

BSE+NSE Vol: 1

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

1 (-99.96%) Volume

Shareholding (Sep 2025)

FII

0.01%

Held by 1 FIIs

DII

0.00%

Held by 0 DIIs

Promoter

38.98%

Who are the top shareholders of the Denis Chem Lab?

06-Jun-2025

The top shareholders of Denis Chem Lab are Anar Himanshu Patel with 21.7%, V-s Holding B.v. at 20.74%, and individual investors holding a combined 27.41%. There are no institutional or pledged promoter holdings reported.

The top shareholders of Denis Chem Lab include Anar Himanshu Patel, who holds the largest share at 21.7%. Following him is V-s Holding B.v., with a stake of 20.74%. Additionally, individual investors collectively hold 27.41% of the company's shares. There are no institutional holdings or pledged promoter holdings reported.

Read More

Who are in the management team of Denis Chem Lab?

06-Jun-2025

As of March 2023, the management team of Denis Chem Lab includes Dinesh B Patel (Chairman), Himanshu C Patel (Managing Director), Gaurang Dalal, Anar H Patel, Gauri Trivedi, and Hemendrakumar C Shah (all Independent Non-Executive Directors).

As of March 2023, the management team of Denis Chem Lab includes the following individuals:<BR><BR>1. Dinesh B Patel - Chairman & Non Executive Director<BR>2. Himanshu C Patel - Executive Director / Managing Director / Promoter<BR>3. Gaurang Dalal - Independent Non Executive Director<BR>4. Anar H Patel - Non Executive Director<BR>5. Gauri Trivedi - Independent Non Executive Director<BR>6. Hemendrakumar C Shah - Independent Non Executive Director<BR><BR>These members play various roles within the company's governance structure.

Read More

What does Denis Chem Lab do?

06-Jun-2025

Denis Chem Lab Ltd manufactures sterile intravenous injectables and IV fluids, operating in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of 41 Cr and a net profit of 1 Cr, with a market cap of Rs 145 Cr.

Overview: <BR>Denis Chem Lab Ltd is a company engaged in the manufacturing of sterile intravenous (IV) injectables and IV fluids, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap.<BR><BR>History: <BR>Denis Chem Lab Ltd was incorporated in 1980 and became a Public Limited Company in 1982. The company started commercial production of sterile IV injectables in 1984 and ventured into manufacturing IV fluids in PP bottles using BFS technology in 1995. The latest reported quarter for net sales and profit is March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 41 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 1 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 145 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 18.00 <BR>Industry P/E: 41 <BR>Dividend Yield: 2.37% <BR>Debt-Equity: -0.29 <BR>Return on Equity: 9.80% <BR>Price to Book: 1.78<BR><BR>Contact Details: <BR>Address: Block No 457 Kalol Taluka, Chhatral Gandhinagar Gujarat : 382729 <BR>Tel: 91-2764-233596/233613 <BR>Email: denishchem401@gmail.com <BR>Website: http://www.denischemlab.com

Read More

Has Denis Chem Lab declared dividend?

06-Jun-2025

Yes, Denis Chem Lab Ltd has declared a 25% dividend, amounting to 2.5 per share, with an ex-date of September 19, 2024. While recent returns have been negative, the company has shown significant growth over the longer term, particularly with a total return of 234.06% over the past five years.

Denis Chem Lab Ltd has declared a 25% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 25%<BR>- Amount per share: 2.5<BR>- Ex-date: 19 Sep 24<BR><BR>Dividend Yield: 2.37%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -36.1%, the dividend return was 0%, resulting in a total return of -36.1%.<BR><BR>Over the past year, the price return was -37.61%, the dividend return was 1.39%, leading to a total return of -36.22%.<BR><BR>In the 2-year period, the price return was 35.7%, the dividend return was 4.70%, which resulted in a total return of 40.4%.<BR><BR>For the last 3 years, the price return was 86.63%, the dividend return was 11.78%, culminating in a total return of 98.41%.<BR><BR>Over the past 4 years, the price return was 59.07%, the dividend return was 12.70%, resulting in a total return of 71.77%.<BR><BR>In the 5-year period, the price return was 213.91%, the dividend return was 20.15%, leading to a total return of 234.06%.<BR><BR>Overall, Denis Chem Lab Ltd has declared a dividend, and while recent returns have been negative in the shorter term, the longer-term returns show significant growth, particularly in the 5-year period.

Read More

Who are the peers of the Denis Chem Lab?

03-Jun-2025

Peers of Denis Chem Lab include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, BDH Industries, Tyche Industries, Quest, and Sotac Pharma. Denis Chem Lab has average management risk, below-average growth, and the lowest 1-year return among its peers at -38.43%.

Peers: The peers of Denis Chem Lab are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, BDH Industries, Tyche Industries, Quest, and Sotac Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, BDH Industries, and Tyche Industries, while Average management risk is found at Denis Chem Lab. Below Average management risk is noted at Sotac Pharma and Vaishali Pharma. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at Divi's Lab., Torrent Pharma, Denis Chem Lab, BDH Industries, Tyche Industries, and Vaishali Pharma. Excellent capital structure is present at Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, BDH Industries, and Tyche Industries, while Good capital structure is noted at Torrent Pharma and Quest, and Average capital structure is found at Sotac Pharma.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.69%, while Denis Chem Lab has the lowest at -38.43%. This indicates that Denis Chem Lab's return is significantly lower than its peers. Additionally, BDH Industries, Tyche Industries, and Denis Chem Lab have negative six-month returns.

Read More

What is the technical trend for Denis Chem Lab?

09-Jun-2025

As of April 30, 2025, Denis Chem Lab's trend is mildly bearish, influenced by daily moving averages and weekly Bollinger Bands, though the weekly MACD is mildly bullish and the monthly RSI is bullish, indicating mixed momentum and a weak bearish sentiment with potential for recovery.

As of 30 April 2025, the technical trend for Denis Chem Lab has changed from bearish to mildly bearish. The current stance is mildly bearish, primarily driven by the daily moving averages indicating a bearish trend and the weekly Bollinger Bands also showing bearish signals. The MACD on a weekly basis is mildly bullish, providing some counterbalance, while the monthly MACD remains mildly bearish. The RSI on a monthly basis is bullish, but with no signal on the weekly, indicating mixed momentum. Overall, the indicators suggest a weak bearish sentiment with some signs of potential recovery in the longer term.

Read More

How big is Denis Chem Lab?

24-Jul-2025

As of 24th July, Denis Chem Lab Ltd has a market capitalization of 139.00 Cr, with recent Net Sales of 173.30 Cr and a Net Profit of 8.08 Cr. The company's Shareholder's Funds are 80.37 Cr and Total Assets amount to 109.35 Cr.

As of 24th July, Denis Chem Lab Ltd has a market capitalization of 139.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 173.30 Cr and a Net Profit of 8.08 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 80.37 Cr and Total Assets of 109.35 Cr.

Read More

When is the next results date for Denis Chem Lab?

06-Aug-2025

Denis Chem Lab will announce its results on 13 August 2025.

Denis Chem Lab will declare its results on 13 August 2025.

Read More

Are Denis Chem Lab latest results good or bad?

13-Aug-2025

Denis Chem Lab's latest results show a mixed picture; while overall performance is flat, key profitability metrics have improved significantly, with Profit Before Tax up 38.1% and a 4.59% increase in net sales, indicating a positive trend. Overall, the results lean towards the positive side.

Denis Chem Lab's latest results present a mixed picture. While the overall financial performance has remained flat compared to previous quarters, there are notable improvements in key profitability metrics. The Profit Before Tax (PBT) increased by 38.1% to Rs 3.02 crore, and the Profit After Tax (PAT) rose by 22.8% to Rs 2.48 crore. These gains indicate a positive trend in the company's profitability.<BR><BR>Additionally, the company's net sales saw a growth of 4.59% compared to the previous quarter, which is a positive sign after a decline in the prior period. The standalone net profit also experienced a remarkable increase of 249.30%, showcasing a strong recovery.<BR><BR>Overall, while the flat performance might raise some concerns, the significant growth in profitability and sales suggests that Denis Chem Lab is on an upward trajectory, making the latest results lean more towards the positive side.

Read More

How has been the historical performance of Denis Chem Lab?

14-Nov-2025

Denis Chem Lab has shown steady growth in net sales and profitability, with net sales increasing from 124.12 Cr in Mar'19 to 173.30 Cr in Mar'25, and profit after tax rising from 6.35 Cr to 8.08 Cr during the same period. The company has also improved its financial stability, reducing total debt significantly while maintaining positive cash flow.

Answer:<BR>The historical performance of Denis Chem Lab shows a steady growth in net sales and profitability over the years.<BR><BR>Breakdown:<BR>Denis Chem Lab's net sales have increased from 124.12 Cr in Mar'19 to 173.30 Cr in Mar'25, reflecting a consistent upward trend. Total operating income has followed a similar trajectory, rising from 124.12 Cr in Mar'19 to 173.30 Cr in Mar'25. However, total expenditure has also increased, from 110.26 Cr in Mar'19 to 157.19 Cr in Mar'25, which has impacted operating profit, which peaked at 22.63 Cr in Mar'24 before declining to 18.48 Cr in Mar'25. Profit before tax has shown improvement from 5.92 Cr in Mar'19 to 11.11 Cr in Mar'25, while profit after tax has increased from 6.35 Cr in Mar'19 to 8.08 Cr in Mar'25. The company's total assets have grown from 97.42 Cr in Mar'20 to 112.27 Cr in Mar'25, alongside a decrease in total debt from 10.51 Cr in Mar'20 to 0.82 Cr in Mar'25, indicating improved financial stability. Cash flow from operating activities has fluctuated but remained positive, with a notable cash flow of 12.00 Cr in Mar'25. Overall, Denis Chem Lab has demonstrated a robust growth trajectory in sales and profitability, alongside a strengthening balance sheet.

Read More

Should I buy, sell or hold Denis Chem Lab?

16-Nov-2025

Is Denis Chem Lab overvalued or undervalued?

18-Nov-2025

As of November 17, 2025, Denis Chem Lab is considered undervalued with a PE ratio of 16.73 and favorable valuation metrics compared to its industry peers, despite a recent stock underperformance of -47.04% against the Sensex.

As of 17 November 2025, Denis Chem Lab's valuation grade has moved from very attractive to attractive, indicating a shift in market perception. The company is currently assessed as undervalued, given its PE ratio of 16.73, EV to EBIT of 8.73, and a Price to Book Value of 1.36. These metrics suggest that the company is trading at a reasonable valuation compared to its peers.<BR><BR>In comparison to its industry, Denis Chem Lab's PE ratio is significantly lower than that of Supreme Industries and Astral, which are both categorized as very expensive with PE ratios of 54.4 and 77.37, respectively. Additionally, the company's EV to EBITDA ratio of 5.94 is more favorable than the industry average, reinforcing its undervaluation status. While the stock has underperformed against the Sensex over the past year, with a return of -47.04% compared to the Sensex's 9.50%, the current valuation metrics suggest that there is potential for recovery and growth moving forward.

Read More

Why is Denis Chem Lab falling/rising?

04-Dec-2025

As of 04-Dec, Denis Chem Lab Ltd's stock price is Rs 84.51, down 0.6%, continuing a four-day decline totaling 3.8%. The stock is underperforming significantly compared to the Sensex, with a year-to-date drop of 49.77% and diminished investor interest.

As of 04-Dec, Denis Chem Lab Ltd's stock price is falling, currently at Rs 84.51, reflecting a decrease of Rs 0.51 or 0.6%. The stock has been on a downward trend, having lost value for the last four consecutive days, resulting in a total decline of 3.8% during this period. Additionally, the stock is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish trend.<BR><BR>The stock's performance over the past month shows a significant decline of 7.87%, contrasting sharply with the Sensex, which has gained 2.16% in the same period. Year-to-date, Denis Chem Lab has experienced a staggering drop of 49.77%, while the Sensex has increased by 9.12%. This trend is further underscored by the stock's performance over the past year, with a decline of 50.58% compared to the Sensex's modest gain of 5.32%.<BR><BR>Investor participation has also diminished, as evidenced by a 74.7% drop in delivery volume on December 3 compared to the 5-day average, suggesting a lack of interest from investors. Furthermore, the stock is close to its 52-week low, being only 2.79% away from Rs 82.15. Overall, these factors contribute to the ongoing decline in the stock price of Denis Chem Lab Ltd.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor long term growth as Net Sales has grown by an annual rate of 7.90% and Operating profit at 14.61% over the last 5 years

 
2

Flat results in Sep 25

3

Below par performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Loading Valuation Snapshot...
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

INR 120 Cr (Micro Cap)

stock-summary
P/E

16.00

stock-summary
Industry P/E

27

stock-summary
Dividend Yield

1.75%

stock-summary
Debt Equity

-0.22

stock-summary
Return on Equity

8.16%

stock-summary
Price to Book

1.35

Revenue and Profits:
Net Sales:
46 Cr
(Quarterly Results - Sep 2025)
Net Profit:
2 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (1.75%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-11.73%
1.53%
-10.2%
6 Months
-18.16%
1.44%
-16.72%
1 Year
-48.82%
0.92%
-47.9%
2 Years
-28.92%
3.45%
-25.47%
3 Years
0%
7.46%
7.46%
4 Years
42.39%
10.05%
52.44%
5 Years
87.23%
18.16%
105.39%

Latest dividend: 1.5 per share ex-dividend date: Sep-19-2025

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions
News

Why is Denis Chem Lab falling/rising?

Recent Price Movement and Market Comparison

Denis Chem Lab’s share price closed at ₹85.30 on 25 November, down by 0.34% or ₹0.29 from the previous close. This decline is part of a broader negative trend, with the stock having fallen by 3.64% over the past week and 5.88% in the last month. These figures stand in stark contrast to the Sensex, which has recorded modest gains of 0.10% and 0.45% over the same respective periods. The divergence highlights the stock’s underperformance amid a generally positive market environment.

Over the year-to-date period, the stock has suffered a severe setback, plunging nearly 49.3%, while the Sensex has advanced by 8.25%. Similarly, the one-year return for Denis Chem Lab is a negative 46.64%, compared to a positive 5.59% for the benchma...

Read More
Announcements stock-summary

Board Meeting Outcome for Board Meeting Outcome For - Submission Of Un-Audited Financial Results For The Quarter Ended On 30Th September 2025

13-Nov-2025 | Source : BSE

Outcome of Board Meeting - Submission of Unaudited Financial Results for the quarter ended on 30th September 2025 and of Limited Review Report thereon

Results - Financial Results For Sep 30 2025

13-Nov-2025 | Source : BSE

Statement of Unaudited Financial Result for the quarter ended on 30th September 2025 alongwith Limited Review Report.

Board Meeting Intimation for For Taking On Record Unaudited Financial Results For The Quarter Ended On 30Th September 2025

05-Nov-2025 | Source : BSE

Denis Chem Lab Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2025 inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter ended on 30th September 2025. Please note that as intimated to the Exchange vide Letter dated 24th September 2025 the Trading Window of the Company shall continue to remain closed for designated persons till 48 hours after the declaration of Financial Results for the quarter ended on 30th September 2025 in terms of Companys Code of Conduct for prevention of Insider Trading and SEBI (Prohibition of Insider Trading) Regulations 2015.

Corporate Actions stock-summary
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

Denis Chem Lab Ltd has declared 15% dividend, ex-date: 19 Sep 25

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

Denis Chem Lab Ltd has announced 2:11 rights issue, ex-date: 07 Sep 17

stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
7.90%
EBIT Growth (5y)
14.61%
EBIT to Interest (avg)
8.94
Debt to EBITDA (avg)
0.25
Net Debt to Equity (avg)
-0.22
Sales to Capital Employed (avg)
1.95
Tax Ratio
27.13%
Dividend Payout Ratio
31.10%
Pledged Shares
0
Institutional Holding
0.01%
ROCE (avg)
17.17%
ROE (avg)
10.38%
Valuation key factors
Factor
Value
P/E Ratio
16
Industry P/E
27
Price to Book Value
1.34
EV to EBIT
8.51
EV to EBITDA
5.79
EV to Capital Employed
1.43
EV to Sales
0.56
PEG Ratio
NA
Dividend Yield
1.77%
ROCE (Latest)
16.81%
ROE (Latest)
8.16%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Non Institution

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 1 FIIs (0.01%)

Promoter with highest holding

Anar Himanshu Patel (21.7%)

Highest Public shareholder

V-s Holding B.v. (20.74%)

Individual Investors Holdings

28.9%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Sep'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 6.68% vs 4.59% in Jun 2025",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is -10.89% vs 249.30% in Jun 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "46.17",
          "val2": "43.28",
          "chgp": "6.68%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "4.26",
          "val2": "6.79",
          "chgp": "-37.26%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.23",
          "val2": "3.58",
          "chgp": "-93.58%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "2.21",
          "val2": "2.48",
          "chgp": "-10.89%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "9.23%",
          "val2": "15.69%",
          "chgp": "-6.46%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is 0.42% vs -46.92% in Sep 2024",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is -16.40% vs -49.73% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "89.45",
          "val2": "89.08",
          "chgp": "0.42%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "9.09",
          "val2": "10.23",
          "chgp": "-11.14%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.42",
          "val2": "0.21",
          "chgp": "100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "4.69",
          "val2": "5.61",
          "chgp": "-16.40%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "10.16%",
          "val2": "11.48%",
          "chgp": "-1.32%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2024 is 3.09% vs 5.65% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2024 is -12.57% vs 18.90% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "131.92",
          "val2": "127.97",
          "chgp": "3.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "14.05",
          "val2": "16.15",
          "chgp": "-13.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.28",
          "val2": "0.31",
          "chgp": "-9.68%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "7.37",
          "val2": "8.43",
          "chgp": "-12.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "10.65%",
          "val2": "12.62%",
          "chgp": "-1.97%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 3.27% vs 4.33% in Mar 2024",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is -27.60% vs 41.98% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "173.30",
          "val2": "167.82",
          "chgp": "3.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "16.11",
          "val2": "21.24",
          "chgp": "-24.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.51",
          "val2": "0.54",
          "chgp": "-5.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "8.08",
          "val2": "11.16",
          "chgp": "-27.60%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "9.30%",
          "val2": "12.66%",
          "chgp": "-3.36%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Standalone) - Sep'25 - QoQstock-summary
Sep'25
Jun'25
Change(%)
Net Sales
46.17
43.28
6.68%
Operating Profit (PBDIT) excl Other Income
4.26
6.79
-37.26%
Interest
0.23
3.58
-93.58%
Exceptional Items
0.00
0.00
Standalone Net Profit
2.21
2.48
-10.89%
Operating Profit Margin (Excl OI)
9.23%
15.69%
-6.46%
Values in Rs Cr.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Sep 2025 is 6.68% vs 4.59% in Jun 2025

Direction Arrows
Standalone Net Profit

QoQ Growth in quarter ended Sep 2025 is -10.89% vs 249.30% in Jun 2025

Half Yearly Results Snapshot (Standalone) - Sep'25stock-summary
Sep'25
Sep'24
Change(%)
Net Sales
89.45
89.08
0.42%
Operating Profit (PBDIT) excl Other Income
9.09
10.23
-11.14%
Interest
0.42
0.21
100.00%
Exceptional Items
0.00
0.00
Standalone Net Profit
4.69
5.61
-16.40%
Operating Profit Margin (Excl OI)
10.16%
11.48%
-1.32%
Values in Rs Cr.
Direction Arrows
Net Sales

Growth in half year ended Sep 2025 is 0.42% vs -46.92% in Sep 2024

Direction Arrows
Standalone Net Profit

Growth in half year ended Sep 2025 is -16.40% vs -49.73% in Sep 2024

Nine Monthly Results Snapshot (Standalone) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
131.92
127.97
3.09%
Operating Profit (PBDIT) excl Other Income
14.05
16.15
-13.00%
Interest
0.28
0.31
-9.68%
Exceptional Items
0.00
0.00
Standalone Net Profit
7.37
8.43
-12.57%
Operating Profit Margin (Excl OI)
10.65%
12.62%
-1.97%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2024 is 3.09% vs 5.65% in Dec 2023

Direction Arrows
Standalone Net Profit

YoY Growth in nine months ended Dec 2024 is -12.57% vs 18.90% in Dec 2023

Annual Results Snapshot (Standalone) - Mar'25stock-summary
Mar'25
Mar'24
Change(%)
Net Sales
173.30
167.82
3.27%
Operating Profit (PBDIT) excl Other Income
16.11
21.24
-24.15%
Interest
0.51
0.54
-5.56%
Exceptional Items
0.00
0.00
Standalone Net Profit
8.08
11.16
-27.60%
Operating Profit Margin (Excl OI)
9.30%
12.66%
-3.36%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is 3.27% vs 4.33% in Mar 2024

Direction Arrows
Standalone Net Profit

YoY Growth in year ended Mar 2025 is -27.60% vs 41.98% in Mar 2024

stock-summaryCompany CV
About Denis Chem Lab Ltd stock-summary
stock-summary
Denis Chem Lab Ltd
Micro Cap
Pharmaceuticals & Biotechnology
Denis Chem Lab Ltd, was incorporated in 1980 and was converted into a Public Limited Company in 1982. The Company was registered with Directorate General of Technical Development (DGTD) for manufacturing 4 million bottles of I.V. Fluids and 75 MT of Bulk Drugs per annum and started commercial production for sterile Intravenous (IV) Injectibles in 1984 and also came up with a rights issue during the year In 1995, it ventured into manufacturing of IV Fluids in PP bottles using BFS technology.
Company Coordinates stock-summary
Company Details
Block No 457 Kalol Taluka, Chhatral Gandhinagar Gujarat : 382729
stock-summary
Tel: 91-2764-233596/233613
stock-summary
denishchem401@gmail.com
Registrar Details